Key Findings
Azunic AI announced its adoption of Inventia Life Science’s RASTRUM 3D cell culture platform for its toxicology assessment programs, aiming to accelerate the development of an animal-free, human-specific 3D in vitro toxicology platform. This strategic partnership represents a significant step forward in streamlining drug safety evaluation and promoting ethical alternatives to animal testing in pharmaceutical development.
Technical & Clinical Details
The RASTRUM platform’s advanced technology enables the scalable generation of reproducible, human-relevant 3D cell models. Its key technical features include:
- Precision Bioprinting: Accurately positions cells and extracellular matrix (ECM) components to construct complex 3D models that mimic in vivo tissue structures. This ensures cell-cell and cell-matrix interactions are reproduced in a more physiologically relevant manner.
- Defined Synthetic Matrices: Utilizes chemically defined synthetic hydrogels as scaffolds, free from animal-derived components. This eliminates batch-to-batch variability, enhances experimental reproducibility, and avoids the risks associated with animal pathogens.
- Workflow-Driven Software: An intuitive and automated software efficiently manages the entire workflow, from model design to culture and analysis. This enables high-throughput toxicology screening.
By leveraging these RASTRUM capabilities, Azunic AI will achieve consistent model production and biologically relevant data generation across its toxicology programs. This is expected to yield more accurate and predictive results for various types of toxicity assessments, including hepatotoxicity, cardiotoxicity, and neurotoxicity. As the data obtained is human-specific, it has the potential to contribute to reducing failure rates in clinical trials compared to animal studies.
Background & Context
Preclinical toxicology assessment is indispensable for ensuring drug safety during pharmaceutical development. However, conventional animal testing is costly, time-consuming, and raises ethical concerns regarding animal welfare. Furthermore, data from animal models do not always accurately reflect human physiology, occasionally leading to unexpected toxicities in clinical phases. Against this backdrop, the development of animal-free alternatives using human-relevant in vitro models has become an urgent priority for the pharmaceutical industry. 3D cell culture technology, capable of reproducing an environment closer to in vivo conditions than 2D cultures, is emerging as a promising solution to this need.
Strategic Significance & Outlook
Azunic AI’s adoption of the RASTRUM platform holds significant implications for revolutionizing drug safety evaluation processes and accelerating the market entry of new medicines. This technology not only enhances the efficiency and accuracy of preclinical toxicology assessments but also contributes to reducing animal testing, thereby improving the overall sustainability and ethical profile of R&D. In the future, such human-relevant 3D models are expected to be applied to a wide range of research areas beyond toxicology, including drug screening, disease model development, and personalized medicine. This partnership marks an important milestone in shaping the future of drug development.
Get our weekly technology intelligence — free
Receive an infographic that lets you judge at a glance whether each field’s analysis report is worth reading.
Subscribe Free — Weekly Tech Intelligence
By subscribing, you’ll receive Troy-Technical’s weekly technology intelligence newsletter.
- Your email and selected fields are used only to deliver the newsletter.
- We never share your information with third parties.
- You can unsubscribe anytime via the link in each email.
See our Privacy Policy for details.
Takes about a minute · Unsubscribe anytime
Comments